PITTSBURGH--(BUSINESS WIRE)--RedPath Integrated Pathology, Inc. (“RedPath”), a cancer molecular diagnostics company headquartered in Pittsburgh, PA, announced that it has received two technology grants from The Internal Revenue Service to support continued development of the company’s flagship PathFinderTG molecular diagnostics platform. The two grants totaling $488,958 were awarded through the IRS Qualifying Therapeutic Discovery Project Program.
